BioNTech carries a favorable risk/reward geometry — 22.6% upside to the analyst-consensus target against 6.5% of measured downside — but that asymmetry sits on top of four consecutive earnings misses, a 35% revenue decline, negative free cash flow, and a quality score well below the minimum threshold; the setup is speculative and the fundamental case requires a clear reversal before conviction is warranted.
Thesis pillars
- Cash Burn Negative Rule Of 40→Stable
- Four Quarter Earnings Miss Streak→Stable
- Revenue Declining 35 Percent→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
BioNTech SE (BNTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $87.99: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial,... Read more
Sell if holding. Engine safety override at $87.99: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — BioNTech SE
Latest news
- NEWS BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit — benzinga Oct 26, 2026 negative
- NEWS BioNTech and DualityBio Announce Positive Topline Results from Phase 3 DYNASTY-Breast02 Trial — fiscal.ai Oct 26, 2026 positive
- NEWS BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Mode — benzinga Oct 26, 2026 positive
- NEWS BioNTech, Bristol Myers Squibb Announced Sunday At ESMO, Phase 2 ROSETTA Lung-107 Data Showing Pumitamig + Docetaxel Ach — benzinga Oct 25, 2026 positive
- NEWS BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Data for Pumitamig in Advanced NSCLC — fiscal.ai Oct 25, 2026 positive
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Insiders leaning net-seller recently. Could be diversification/taxes rather than view, but the signal is not supportive.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Unprofitable operations — net margin -63.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $87.99: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $82.45. Score 4.6/10, moderate confidence.
Analyst target: $104.43 (+18.7% upside). Prior stop was $82.45. Stop-loss: $82.45.
Quality below floor (3.4 < 4.0).
BioNTech SE trades at a P/E of N/A (forward -16.3). TrendMatrix value score: 6.3/10. Verdict: Sell.
28 analysts cover BNTX with a consensus score of 4.0/5. Average price target: $116.
What does BioNTech SE do?BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in...
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.